Citable filing context
INSM's research view summarizes recent SEC filing context, starting with earnings from Aug 6, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 6, 2026 | earnings | Insmed reported second-quarter 2026 total revenues of $425.5 million and raised its full-year BRINSUPRI revenue guidance. |
| Jul 16, 2026 | other | Insmed announced positive 12-month data from an open-label extension study of TPIP in patients with pulmonary arterial hypertension. |
| May 15, 2026 | management_change | Insmed shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins as Class II directors. |
| Aug 6, 2026 | Guidance: arikayce_revenue | 450.00 to 470.00 |
| Aug 6, 2026 | Guidance: brinsupri_revenue | 1250.00 to 1400.00 |
| May 7, 2026 | Guidance: arikayce_revenue | 450.00 to 470.00 |
| Aug 6, 2026 | mda_quarterly | Insmed’s financial performance for the first half of 2026 reflects a significant transition driven by the commercial launch of BRINSUPRI (brensocatib). Total product revenues reached $731.5 million for the six-month period, a 265% increase year-over-year, primarily fueled by $515.7 million in U.S. sales of BRINSUPRI. ARIKAYCE continues to provide a stable revenue base, contributing $214.4 million, with growth concentrated in international markets. Despite rising revenues, the company remains in a growth-investment phase, reporting a net loss of $176.8 million for the six months ended June 30, 2026. Operating expenses are elevated due to aggressive commercialization efforts for BRINSUPRI and ongoing R&D investment in the respiratory pipeline, particularly TPIP, which saw an 89% increase in external R&D spending during the second quarter. Liquidity remains sufficient, with $1.16 billion in combined cash and marketable securities as of June 30, 2026. Management expects these funds to support operations for at least the next 12 months. Key risks include the successful execution of clinical trials for TPIP and the gene therapy programs (INS1201 and INS1202), potential regulatory hurdles in international markets, and the ongoing requirement to manage substantial debt and contingent consideration obligations. |
| May 7, 2026 | mda_quarterly | Insmed reported a significant transformation in its financial profile for the first quarter of 2026, driven by the commercial launch of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis (NCFB). Total product revenues reached $306.0 million, a 229.6% increase year-over-year, primarily fueled by $207.2 million in U.S. sales of BRINSUPRI. ARIKAYCE continued to perform steadily, contributing $98.1 million in global revenue, a 5.7% increase. Despite rising revenues, the company remains in a growth and investment phase, reporting a net loss of $163.6 million for the quarter. Operating expenses were elevated by substantial R&D investments ($209.5 million) and SG&A costs ($247.3 million) associated with the BRINSUPRI launch and ongoing clinical trials for TPIP (pulmonary hypertension and fibrosis) and gene therapies INS1201 and INS1202. Liquidity remains robust, with $1.22 billion in combined cash and marketable securities as of March 31, 2026. Management expects these funds to support operations for at least the next 12 months. Key upcoming milestones include a U.S. supplemental NDA submission for ARIKAYCE in the second half of 2026 following positive ENCORE study results, and continued Phase 3 development of TPIP. The company has discontinued its development program for brensocatib in hidradenitis suppurativa following negative Phase 2b results. |
Source: SEC EDGAR filing text and events; period Aug 6, 2026; filed Aug 6, 2026.
INSM company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.